Castle Biosciences Shares Decline Amid Acquisition Plans

Castle Biosciences shares are trading lower after announcing their agreement to acquire Capsulomics, Inc., d/b/a Previse, indicating potential market concerns over the acquisition's impact on financials and operational focus.